Premium
Endocrine disrupting‐chemicals and biochemical recurrence of prostate cancer after prostatectomy: A cohort study in Guadeloupe (French West Indies)
Author(s) -
Brureau Laurent,
Emeville Elise,
Helissey Carole,
Thome Jean Pierre,
Multigner Luc,
Blanchet Pascal
Publication year - 2019
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.32287
Subject(s) - prostate cancer , congener , prostatectomy , hazard ratio , medicine , endocrine system , quartile , confidence interval , biochemical recurrence , cohort , gynecology , physiology , oncology , urology , cancer , endocrinology , hormone , chemistry , environmental chemistry
Previous studies have suggested that exposure to environmental chemicals with hormonal properties, also called endocrine disrupting chemicals, may be involved in the occurrence of prostate cancer (PCa). Such exposure may also influence the treatment outcome as it is still present at the time of diagnosis, the beginning of therapy, and beyond. We followed 326 men in Guadeloupe (French West Indies) who underwent radical prostatectomy as primary treatment of localized PCa. We analyzed the relationship between exposure to the estrogenic chlordecone, the antiandrogenic dichlorodiphenyldichloroethylene (DDE, the main metabolite of the insecticide DDT), and the nondioxin‐like polychlorinated biphenyl congener 153 (PCB‐153) with mixed estrogenic/antiestrogenic properties and the risk of biochemical recurrence (BCR) after surgery. After a median follow‐up of 6.1 years after surgery, we found a significant increase in the risk of BCR, with increasing plasma chlordecone concentration (adjusted hazard ratio = 2.51; 95% confidence interval: 1.39–4.56 for the highest vs . lowest quartile of exposure; p trend = 0.002). We found no associations for DDE or PCB‐135. These results shown that exposure to environmental estrogens may negatively influence the outcome of PCa treatment.